Thalassemia-free and graft-versus-host-free survival: Outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience
![](/xmlui/themes/Mirage2//images/mime.png)
Access
info:eu-repo/semantics/closedAccessDate
2022Author
Yeşilipek, Mehmet AkifUygun, Vedat
Küpesiz, Alphan
Karasu, Gülsün
Öztürk, Gülyüz
Ertem, Mehmet
Şaşmaz, İlgen
Daloğlu, Hayriye
Güler, Elif
Hazar, Volkan
Fışgın, Tunç
Sezgin, Gülay
Kansoy, Savaş
Kuşkonmaz, Barışl
Akıncı, Burcu
Özbek, Namık
Ünal İnce, Elif
Öztürkmen, Seda
Tayfun Küpesiz, Funda
Yalçın, Koray
Anak, Sema
Bozkurt, Ceyhun
Karakükçü, Musa
Küpeli, Serhan
Albayrak, Davut
Öniz, Haldun
Aksoylar, Serap
Okur, Fatma Visal
Albayrak, Canan
Demir Yenigürbüz, Fatma
Ok Bozkaya, İkbal
İleri, Talia
Gürsel, Orhan
Karagün, Barbaros Şahin
Tüysüz Kintrup, Gülen
Çelen, Suna
Elli, Murat
Adaklı Aksoy, Başak
Yılmaz, Ebru
Tanyeli, Atila
Turan Akyol, Şule
Önder Siviş, Zühal
Özek, Gülcihan
Uçkan, Duygu
Kartal, İbrahim
Atay, Didem
Akyay, Arzu
Arman Bilir, Özlem
Çakmaklı, Hasan Fatih
Kürekçi, Emin
Malbora, Barış
Akbayram, Sinan
Demir, Hacı Ahmet
Çakı Kılıç, Suar
Güneş, Adalet Meral
Zengin, Emine
Özmen, Salih
Antmen, Ali Bülent
Metadata
Show full item recordCitation
Yeşilipek, M. A., Uygun, V., Küpesiz, A., Karasu, G., Öztürk, G., Ertem, M. ... Antmen, A. B. (2022). Thalassemia-free and graft-versus-host-free survival: Outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience. Bone Marrow Transplantation, 57(5), 760-767. https://doi.org/10.1038/s41409-022-01613-wAbstract
We report the national data on the outcomes of hematopoietic stem cell transplantation (HSCT) for thalassemia major (TM) patients in Turkey on behalf of the Turkish Pediatric Stem Cell Transplantation Group. We retrospectively enrolled 1469 patients with TM who underwent their first HSCT between 1988 and 2020 in 25 pediatric centers in Turkey. The median follow-up duration and transplant ages were 62 months and 7 years, respectively; 113 patients had chronic graft versus host disease (cGVHD) and the cGVHD rate was 8.3% in surviving patients. Upon the last visit, 30 patients still had cGvHD (2.2%). The 5-year overall survival (OS), thalassemia-free survival (TFS) and thalassemia-GVHD-free survival (TGFS) rates were 92.3%, 82.1%, and 80.8%, respectively. cGVHD incidence was significantly lower in the mixed chimerism (MC) group compared to the complete chimerism (CC) group (p < 0.001). In survival analysis, OS, TFS, and TGFS rates were significantly higher for transplants after 2010. TFS and TGFS rates were better for patients under 7 years and at centers that had performed over 100 thalassemia transplants. Transplants from matched unrelated donors had significantly higher TFS rates. We recommend HSCT before 7 years old in thalassemia patients who have a matched donor for improved outcomes.
WoS Q Kategorisi
Q2xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q1Source
Bone Marrow TransplantationVolume
57Issue
5Collections
- Makale Koleksiyonu [3790]
- PubMed İndeksli Yayınlar Koleksiyonu [4251]
- Scopus İndeksli Yayınlar Koleksiyonu [6601]
- WoS İndeksli Yayınlar Koleksiyonu [6677]